Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...
Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...
Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach ...
BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...
We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...
Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
MacroGenics, Inc.’s MGNX share price has dipped by 12.85%, which has investors questioning if this is right time to buy.
Zacks Investment Research on MSN1d
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback